002019 Stock Overview
Engages in the researches and develops, produces, and sells macromolecules, biosimilars, generic drugs, small molecules, synthetic biologics, and special traditional Chinese medicines in China Southeast Asia, Europe, North America, Singapore, South Korea, Italy, Germany, and the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Yifan Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.36 |
| 52 Week High | CN¥15.30 |
| 52 Week Low | CN¥9.11 |
| Beta | 0.93 |
| 1 Month Change | -7.34% |
| 3 Month Change | 11.92% |
| 1 Year Change | -24.37% |
| 3 Year Change | -31.57% |
| 5 Year Change | -28.69% |
| Change since IPO | 536.16% |
Recent News & Updates
Does Yifan Pharmaceutical (SZSE:002019) Have A Healthy Balance Sheet?
Oct 11
Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price Could Signal Some Risk
Sep 11Recent updates
Does Yifan Pharmaceutical (SZSE:002019) Have A Healthy Balance Sheet?
Oct 11Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price Could Signal Some Risk
Sep 11These 4 Measures Indicate That Yifan Pharmaceutical (SZSE:002019) Is Using Debt Extensively
Jun 04Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Shares Leap 28% Yet They're Still Not Telling The Full Story
May 08A Piece Of The Puzzle Missing From Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price
Mar 01Shareholder Returns
| 002019 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.1% | -1.9% | -1.2% |
| 1Y | -24.4% | -1.8% | 11.8% |
Return vs Industry: 002019 underperformed the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 002019 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 002019 volatility | |
|---|---|
| 002019 Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002019 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002019's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 4,230 | Xian Feng Cheng | www.yifanyy.com |
Yifan Pharmaceutical Co., Ltd. engages in the researches and develops, produces, and sells macromolecules, biosimilars, generic drugs, small molecules, synthetic biologics, and special traditional Chinese medicines in China Southeast Asia, Europe, North America, Singapore, South Korea, Italy, Germany, and the United States, and internationally. It offers oral slow controlled release preparations, micron suspensions, micelles for injection, and liquid preparations. The company also focuses on hematologic maliganancies, inflammatory, endocrinology/metabolic, dermatological, gynecologic, and pediatric diseases, etc. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd.
Yifan Pharmaceutical Co., Ltd. Fundamentals Summary
| 002019 fundamental statistics | |
|---|---|
| Market cap | CN¥13.82b |
| Earnings (TTM) | -CN¥331.54m |
| Revenue (TTM) | CN¥5.00b |
2.8x
P/S Ratio-41.7x
P/E RatioIs 002019 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002019 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.00b |
| Cost of Revenue | CN¥2.71b |
| Gross Profit | CN¥2.28b |
| Other Expenses | CN¥2.62b |
| Earnings | -CN¥331.54m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 45.73% |
| Net Profit Margin | -6.64% |
| Debt/Equity Ratio | 29.2% |
How did 002019 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield-37%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 06:44 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yifan Pharmaceutical Co., Ltd. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shitong Han | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Liang Liang | First Capital Securities Co. LTD. |